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The objective of the study was to treat fatigue in patients with multiple sclerosis (MS) by a neurocognitive rehabilitation program
aimed at improving motor planning by using motor imagery (MI). Twenty patients with clinically deﬁnite MS complaining
of fatigue were treated for ﬁve weeks with exercises of neurocognitive rehabilitation twice a week. Patients were evaluated by
Fatigue Severity Scale (FSS), Modiﬁed Fatigue Impact Scale (MFIS), MSQoL54, Expanded Disability Status Scale (EDSS), and
MS Functional Composite (MSFC). After treatment, a decrease in fatigue was detected with both FSS (P = 0.0001) and MFIS
(P = 0.0001). MSFC (P = 0.035) and MSQoL54 (P = 0.002) scores improved compared to baseline. At six-month followup, the
improvement was conﬁrmed for fatigue (FSS, P = 0.0001; MFIS P = 0.01) and for the physical subscale of MSQoL54 (P = 0.049).
No diﬀerences in disability scales were found. These results show that neurocognitive rehabilitation, based on MI, could be a
strategy to treat fatigue in MS patients.
1.Introduction
Fatigue is one of the most common and disabling symptoms
of multiple sclerosis (MS), aﬀecting up to 70% of patients
[1]. It is often present in the earliest phase of the disease and
it is described as the worst symptom by 40–50 % of patients
[2]. Though there is still no accepted deﬁnition, fatigue in
neurological disorders is deﬁned by Chaudhuri and Behan as
“a diﬃcultyininitiationoforsustainingvoluntaryactivities”
[3]. Fatigue is a multidimensional symptom since both
physical and cognitive aspects are present. In MS, fatigue
is primary or secondary to other conditions such as sleep
disturbances, depression, or the use of immunomodulating
therapies [4]. The pathogenesis of primary fatigue in MS is
still unclear, but recent evidences from electrophysiological
and neuroimaging studies supported the hypothesis of a
central origin. Using positron emission tomography (PET),
Roelcke et al. showed reduced glucose metabolism in the
frontal lobe and basal ganglia in MS patients with fatigue
[5]. More recently, proton magnetic resonance spectroscopy
imaging revealed widespread axonal damage in MS patients
with fatigue [6]. Electrophysiological studies [7, 8] gathered
additional evidence for frontal lobe cortical dysfunction in
MS patients complaining of fatigue. In a review, Chaudhuri
and Behan hypothesized that central fatigue may be caused
by a failure in the integration of the limbic input and the
motor functions within the basal ganglia, thus aﬀecting the
striatal-thalamic-frontal cortical system [9]. This hypothesis
has been supported by further studies which suggested an
association between fatigue and damage in the basal ganglia
or thalamus [10]. Indeed, a functional magnetic resonance
imaging (fMRI) study demonstrated an altered recruitment
of the brain sensorimotor network (including the thalamus,
the cerebellum, the frontal lobe, and the cingulum) in MS
patients complaining of fatigue [11]. Although these studies
suggest that fatigue is related to underlying MS pathology
such as demyelization or axonal loss, other possible causes,2 Rehabilitation Research and Practice
such as temperature and immune factors, may play an
important role in the genesis of fatigue [12].
Fatiguemanagementisverydiﬃcult.Manydrugs,thatis,
amantadine,modaﬁnil,andaminopyridines,havebeenused,
butnopharmacologicaltreatmentprovedtobeeﬀective[13–
15]. Also nonpharmacological therapies, based on physical
exercise, behavioural, nutritional, and physiological training,
have been tested [16, 17]. Among them, aerobic exercise,
yogaandcoolingtherapyshowedafavourableeﬀect[18–21].
Some studies focusing on rehabilitation in MS demonstrated
a transitory positive eﬀect in reducing fatigue symptoms
[22], but other studies, which tested the eﬃcacy of diﬀerent
speciﬁc rehabilitation programs on fatigue as compared to
placebo, did not show any diﬀerences [23, 24].
Considering as the origin of fatigue a dysfunction of
the circuits connecting the thalamus, the basal ganglia, and
the frontal cortex which are involved in motor planning
and execution, we hypothesized that this symptom could be
reduced by a speciﬁc neurocognitive rehabilitation program,
based on the neurocognitive theory of rehabilitation (NTR)
and aimed at improving motor planning by using motor
imagery (MI) [25].
MI has already been used in the rehabilitation of
central nervous system (CNS) diseases, especially, as a new
approach, in stroke patients. Sharma et al. suggested that MI
trainingmighthaveanencouragingeﬀectonmotorfunction
after stroke, although the interpretation of the results was
limited by the small sample size and the heterogeneity of
subjects’ characteristics [26, 27].
The objective of this study was to test the eﬃcacy of such
atreatmentinasampleofMSpatientssuﬀeringfromfatigue.
2. Patientsand Methods
2.1.Patients. TwentypatientswithclinicallydeﬁniteMS[28]
(18 women, 2 men; mean age 42.2 (SD 9.7) years, disease
duration 6.9 (SD 4.5) years; median Expanded Disability
Status Scale (EDSS) [29] score 2.0 (range 1.0–6.0; mean 2.45
(SD 1.29)) complaining of fatigue were enrolled. Sixteen
patients had a relapsing-remitting (RR) disease course, three
had a secondary progressive course (SP), and one had a
primary progressive (PP) course. Patients with dementia
(Mini Mental Status Scale [30] <24) or major depression
(Beck’s Depression Inventory Scale [31] >16) were excluded,
as well as patients who underwent concomitant therapy
with antidepressant, psychoactive, steroid, or intravenous
immunosuppressive drugs. Eighteen patients were taking
disease modifying therapy (interferon beta 15, glatiramer
acetate 2, and azathioprine 1) while two patients had no
therapy.
At baseline, the patients were enrolled by a neurologist
who assessed clinical disability, fatigue, and quality of life.
Fatigue was evaluated according to the Fatigue Severity Scale
(FSS) [32] and an Italian version of the Modiﬁed Fatigue
Impact Scale (MFIS) [33], which is divided into physical
(pMFIS), cognitive (cMFIS), and psychosocial (psMFIS)
subscales.MSQoL54,dividedintophysicalandmentalhealth
composite score (PHCS and MHCS) [34], was used to
assess quality of life, while disability was evaluated by using
the EDSS [29] and MS Functional Composite (MSFC)
which consists of three components: 25-Foot Walking Test
(25FWT), Nine-Hole Peg Test (NHPT), and Paced Auditory
Serial Addition Test (PASAT) [35].
The study was approved by the local ethical committee
and all patients gave their written informed consent.
2.2. Treatment Description. All patients were treated for ﬁve
weeks with two sessions per week of a rehabilitation treat-
ment based on the neurocognitive theory of rehabilitation
(NTR), for a total of ten sessions. The basic hypothesis
of NTR is that, through the correct activation of the
patient’s cognitive processes, such as attention, memory,
language, and MI, the CNS could improve movement also
in pathological conditions [25, 36]. The treatment program
consisted in exercises, whose aim was to modify wrong
strategies in motor planning using MI. Before motor execu-
tion, kinaesthetic information was collected and processed
to help planning and controlling movement. Attention and
perception are fundamental functions for the integration
of these processes. During the exercises the physiotherapist
gave to the patients a cognitive/motor problem to be solved
through the movement of body segments, performed with
the physiotherapist help. Each exercise focused on one
subfunction (i.e., shifting weight on one limb, raising an
arm) of a complex movement (i.e., walking, combing one’s
hair). The patient was asked to select, without sight con-
trol, the most important complex kinaesthetic information
generated by that particular movement. Then, by using the
collected information, the subject was guided to create self-
generated MI [37], in the attempt to modify the movement
representation before its execution. The correct execution of
MI was checked by temporal coupling and patient’s verbal
description. Finally, the movement was experienced by the
patient himself, comparing imagined to actual movement,
in order to consciously detect wrong motor strategies. The
solution of the problem is therefore strictly connected to the
correct creation of MI, the collection and interpretation of
kinaesthetic information, and the proper execution of the
movement.
Along the period of training, each patient was followed
by the same expert physiotherapist on a “one-to-one” basis.
During the study, patients did not undergo any other
rehabilitation treatment.
2.3. Followup. At the end of the ﬁve weeks of treatment (ﬁrst
followup) and six months thereafter (second followup), a
neurologist reevaluated the patient with the same methods
used at baseline. Patients’ level of satisfaction about treat-
ment was also registered. Score changes between baseline
and ﬁrst and second followup were compared using a
nonparametric Wilcoxon’s test for paired samples.
3. Results
3.1. First Follow-Up Evaluation. All patients completed the
programmed treatment. Clinical variable scores before andRehabilitation Research and Practice 3
Table 1: Mean clinical variable scores at baseline and after ﬁve
weeks of treatment (n = 20).
Variable Baseline mean
(SD)
First
follow-up
mean (SD)
P
EDSS 2.45 (1.29) 2.48 (1.26) N.S.
FSS 5.66 (0.48) 4.20 (1.07) <0.0001
MFIS 36.50 (14.28) 23.80 (12.40) <0.0001
pMFIS 20.15 (6.33) 13.45 (6.68) <0.0001
cMFIS 14.15 (8.36) 8.55 (6.16) <0.0001
psMFIS 2.20 (2.12) 1.70 (1.53) 0.133
MSFC 0.10 (0.61) 0.21 (0.56) 0.035
NHPT 22.04 (5.73) 21.04 (4.34) 0.083
25FWT 5.83 (1.78) 5.58 (1.94) 0.093
PASAT 39.55 (12.09) 41.65 (13.19) 0.095
MSQOL-54
PHCS 52.46 (17.08) 65.17 (15.98) 0.002
MHCS 60.78 (16.80) 70.48 (16.33) 0.004
EDDS: Expanded Disability Status Scale, MSFC: Multiple Sclerosis Func-
tional Composite, NHPT: Nine-Hole Peg Test, 25 FWT: 25-Foot Walking
Test, PASAT: Paced Auditory Serial Addition Test, FSS: Fatigue Severity
Scale, MFIS: Modiﬁed Fatigue Impact Scale, pMFIS: physical MFIS
subscale, cMFIS: cognitiveMFIS subscale, psMFIS: psychosocialMFIS sub-
scale, MSQOL-54: Multiple Sclerosis Quality of Life Questionnaire, PHCS:
Physical Health Composite Score, MHCS: Mental Health Composite Score.
after ﬁve weeks of treatment are shown in Table 1.N o
diﬀerences between baseline and ﬁrst follow-up EDSS scores
were found. All patients reported a subjective improvement
of their symptoms after treatment. A signiﬁcant decrease in
fatigue scale scores was detected both with FSS (P = 0.0001)
and MFIS (P = 00001). Considering the MFIS subscales,
signiﬁcant diﬀerences were found for pMFIS (P = 0.0001)
andcMFIS(P = 0.0001)butnotforthepsMFIS(P = 0.133).
The MSFC score was signiﬁcantly improved compared to
baseline (P = 0.035). Taking into consideration separately
the three components of MSFC, the diﬀerences showed only
trendsbutdidnotreachstatisticalsigniﬁcance.Qualityoflife
signiﬁcantly improved, since both PHCS (P = 0.002) and
MHCS (P = 0.004) scores increased after treatment.
3.2. Second Follow-Up Evaluation. After six months, 18
patients were reevaluated. Two patients were excluded for
the development of major depression. Between the ﬁrst
and second followup, two patients experienced one clinical
relapse each and were treated with high doses of intravenous
methylprednisolone (one gram × 5 days) with complete
recovery. Time elapsed from both relapses and the follow-up
evaluation was longer than 30 days.
Compared to baseline, a signiﬁcant favourable change
was conﬁrmed for fatigue symptoms reﬂected by the reduc-
tion in fatigue scales score: FSS (P = 0.0001), MFIS (P =
0.01), pMFIS (P = 0.025), and cMFIS (0.009). Furthermore,
there was a trend for reduced psMFIS score (P = 0.054).
Quality of life assessment showed a signiﬁcant improvement
in PHCS (P = 0.049) but not in MHCS (P = 0.30).
Table 2: Mean clinical variables scores at baseline and 6 months
after treatment (n = 18).
Variable Baseline
mean (SD)
Second
follow-up
mean (SD)
P
EDSS 2.50 (1.34) 2.53 (1.63) N.S.
FSS 5.72 (0.47) 4.17 (1.31) <0.0001
MFIS 36.67 (13.76) 26.78 (17.65) 0.010
pMFIS 20.28 (6.35) 15.71 (8.87) 0.025
cMFIS 14.33 (8.20) 9.72 (8.50) 0.009
psMFIS 2.06 (2.01) 1.33 (1.81) 0.054
MSFC 0.10 (0.63) 0.22 (0.64) 0.122
NHPT 22.21 (5.96) 20.97 (4.44) 0.220
25FWT 5.80 (1.83) 5.77 (2.57) 0.108
PASAT 39.56 (12.45) 41.89 (14.41) 0.216
MSQOL-54
PHCS 52.80 (16.64) 60.78 (17.80) 0.049
MHCS 61.19 (15.56) 65.03 (18.48) 0.309
EDDS: Expanded Disability Status Scale, MSFC: Multiple Sclerosis Func-
tional Composite, NHPT: Nine-Hole Peg Test, 25 FWT: 25-Foot Walking
Test, PASAT: Paced Auditory Serial Addition Test, FSS: Fatigue Severity
Scale, MFIS: Modiﬁed Fatigue Impact Scale, pMFIS: physical MFIS
subscale, cMFIS: cognitiveMFIS subscale, psMFIS: psychosocial MFIS sub-
scale, MSQOL-54: Multiple Sclerosis Quality of Life Questionnaire, PHCS:
Physical Health Composite Score, MHCS: Mental Health Composite Score.
No diﬀerences were detected for EDSS and MSFC scores
(Table 2).
4. Discussion
Wrong strategies of movement planning, even if uncon-
scious, may contribute to the development of fatigue in
patients with MS. This hypothesis is mainly supported
by functional neuroimaging studies, which suggested that
fatigue in MS could result from altered connection between
cortical and sub-cortical areas involved in motor planning
[8–11].
The premise of neurocognitive rehabilitation is to utilize
a patient’s strength to overcome weaknesses. Thus, the
identiﬁcation of individualized compensation strategies will
result in less allocation of attention resources and less
expanded eﬀo r t ,w h i c hi sl i k e l yt of a v o u r a b l yi m p a c to n
fatigue severity and presence. Starting from this hypothesis,
we tested the eﬃcacy of a novel rehabilitation treatment
which helps the patient to detect wrong strategies of motor
planning and to learn more eﬃcient movement execution,
by using exercises based on MI, which basically is a process
of mental simulation or rehearsal of actual movement. MI
is a neurocognitive rehabilitation technique used in the
treatment of chronic disorders other than MS (i.e., stroke),
however, not speciﬁcally focusing on fatigue [26, 27]. MI
is deﬁned as a dynamic state, governed by the principles
of central motor control, during which the representation
of a speciﬁc motor action is internally reactivated within
the working memory without any overt motor output4 Rehabilitation Research and Practice
[38, 39]. Previous studies demonstrated a close temporal
coupling between MI and actual movement, that is, the time
taken to mentally perform an action that closely mirrors
the actual movement [38]. Furthermore, during imagined
movement, the reduction in accuracy with increasing speed
is maintained and the asymmetry between dominant and
nondominant hand is also preserved [39]. Finally, functional
studieshaveshownthatMIandexecutedmovementsactivate
similar pathways [40], thus supporting the idea that MI
is an integral part of the wider motor system that can be
represented by internal models or programs, which develop
over time and are consistently changing.
The patients included in this study had no or only
minimal disability (median EDSS score 2.0), nonetheless,
any motor or cognitive task caused clinically relevant fatigue
symptoms. We supposed a distortion of the representation of
movement which could be correlated with the development
of fatigue, even in patients where motor dysfunction is not
clinically evident yet. The patient’s verbal description of MI
has been analysed to recognize the way she/he processed MI
related to speciﬁc movements. This analysis enabled us to
detect wrong eﬀort strategies, that seem to be present already
withinMI,accordingtothepresenceofa“chaoticMI”which
has been deﬁned as an inability to perform MI accurately or
asatemporaluncouplingtypicalofsubjectswithSNClesions
[26].
During exercise the physiotherapists guided the subjects
to the correct perception of kinaesthetic information result-
ing in a more physiologic motor program that produced less
or no fatigue and a better quality of executed movement,
observed after the 5-week treatment. Our rehabilitation
approach should lead the patients to learn new strategies of
motor planning which might endure after treatment.
In this sample of patients, the proposed treatment
signiﬁcantly reduced fatigue symptoms and improved to
some extent also quality of life and disability. The results are
particularlypromising sincetheimprovement wasdetectable
also in the long-term followup, implying the acquisition of
durable, more eﬀective, motor strategies in these patients.
In fact, the neurocognitive rehabilitation program showed
a signiﬁcant favourable impact on fatigue symptoms. This
beneﬁt persisted six months after the training. The treatment
showed also a beneﬁcial impact on quality of life and disabil-
ity, but this eﬀect disappeared on the 6-month followup, in
line with the results of other rehabilitation therapies in MS
[41]. The selective eﬃcacy on fatigue symptoms six months
after treatment is, in our opinion, an important result
whichsuggestsafocusedeﬀectoftheproposedrehabilitation
program. To maintain and apply the correct strategies of
motor planning over time, a program of periodic retraining
twice a year seems advisable.
The present study has some methodological limitations,
such as the lack of a control group and the small sample size.
Infurtherstudies,alargersamplesizeandacomparisonwith
a control group on another active treatment (i.e., aerobic
exercise) would be advisable. Due to the lack of a control
group, a partial placebo eﬀect cannot be excluded, espe-
cially in fatigue, which can only be measured subjectively.
Nonetheless, we believe that the results are interesting and
warrant further studies to be conﬁrmed, not only for the sig-
niﬁcant quantitative improvement in the fatigue scale scores
but also for the qualitative amelioration of motor strategies
attested by the physiotherapists at the end of the training
and the persistence of the favourable eﬀect on fatigue at the
long-term followup, which is unlikely for a placebo eﬀect.
Although the PASAT test is a good marker of attention and
speed processing, since the treatment requires a high level of
attention, a thorough neuropsychological evaluation should
be advisable before initiating the treatment
To expand research in this topic, an fMRI study in MS
patients with and without fatigue and in healthy controls,
with the aim to compare the patterns of activation in
the cerebral cortex during a simple motor task, is under
completion in our institution. It will be interesting in such
a study to observe the changes of activation patterns after a
training based on neurocognitive rehabilitation treatment to
objectively conﬁrm the modiﬁcation of motor strategies in
treated patients.
In conclusion, our data suggest that neurocognitive
rehabilitation based on MI could be an interesting approach
for the management of fatigue symptoms in MS patients
and that this strategy deserves further controlled studies to
conﬁrm its eﬃcacy. Since in this sample of patients this
treatment had a rapid eﬀect, which tended to persist for
some months, retraining may improve the eﬃcacy in the
longterm.
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